glp-1 drugs metformin TrimRX How GLP-1 medications are transforming

Stanciu GD, Luca A, Rusu RN, Bild V, Beschea Chiriac SI, Solcan C, et al

Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis

The immediate priority is to address the drug delivery challenge

This, in turn, also decreases the risk of infections due to injections

High-resolution LC-MS techniques enable precise molecular weight confirmation, peptide mapping, and structural characterization of GLP-1 therapeutics

Abbreviations CVE: Cardiovascular event EHR: Electronic health record GLP-1RA: Glucagon-like peptide-1 receptor agonist MACE: Major adverse cardiovascular events NAFLD: Non-alcoholic fatty liver disease NASH: Non-alcoholic steatohepatitis PCI: Percutaneous coronary intervention PSM: Propensity score matching SGLT2: Sodiumglucose cotransporter 2 SMD: Standardised mean difference TG: Triacylglycerol References Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes